title: Correlation of LMP10 expression and clinical outcome in Human Papillomavirus (HPV) positive and HPV-Negative tonsillar and base of tongue cancer.
abstract: OBJECTIVE
  To examine LMP10 expression and its possible impact on clinical outcome in human papillomavirus (HPV) positive and HPV-negative tonsillar and base of tongue squamous cell carcinoma (TSCC and BOTSCC).
  
  
  BACKGROUND
  Outcome is better in HPV-positive TSCC and BOTSCC compared to matching HPV-negative tumours, with roughly 80% vs. 40% 5-year disease free survival (DFS) with less aggressive treatment than today's chemoradiotherapy. Since current treatment often results in harmful side effects, less intensive therapy, with sustained patient survival would be an attractive alternative. However, other markers together with HPV status are necessary to select patients and for this purpose LMP10 expression is investigated here in parallel to HPV status and clinical outcome.
  
  
  METHODS
  From 385 patients diagnosed between 2000 and 2007 at the Karolinska University Hospital, 278 formalin fixed paraffin embedded TSCC and BOTSCC biopsies, with known HPV DNA status, were tested for LMP10 nuclear and cytoplasmic expression (fraction of positive cells and staining intensity). The data was then correlated to clinical outcome.
  
  
  RESULTS
  An absent/low compared to a moderate/high LMP10 nuclear fraction of positive cells was correlated to a better 3-year DFS in the HPV-positive group of patients (log-rank p = 0.005), but not in the HPV-negative group. In the HPV-negative group of patients, in contrast to the HPV-positive group, moderate/high LMP10 cytoplasmic fraction and weak/moderate/high LMP10 cytoplasmic intensity correlated to a better 3-year DFS (p = 0.003 and p = 0.001) and 3-year overall survival (p = 0.001 and 0.009).
  
  
  CONCLUSIONS
  LMP10 nuclear expression in the HPV-positive group and LMP10 cytoplasmic expression in the HPV-negative group of patients correlated to better clinical outcome.
authors.affiliation: Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Tertipis
authors.affiliation: Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Linnea
authors.initials: L
authors.lastname: Haeggblom
authors.affiliation: Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Cecilia
authors.initials: C
authors.lastname: Nordfors
authors.affiliation: Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Grün
authors.affiliation: Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Anders
authors.initials: A
authors.lastname: Näsman
authors.affiliation: Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Andrea
authors.initials: A
authors.lastname: Vlastos
authors.affiliation: Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Tina
authors.initials: T
authors.lastname: Dalianis
authors.affiliation: Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Torbjörn
authors.initials: T
authors.lastname: Ramqvist
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002467:Cell Nucleus / Q000378:metabolism; D018572:Disease-Free Survival; D005260:Female; D015395:Histocompatibility Antigens Class I / Q000378:metabolism; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D030361:Papillomavirus Infections / Q000378:metabolism* / Q000473:pathology / Q000821:virology; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism*; D013194:Staining and Labeling; D014062:Tongue Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000821:virology*; D014067:Tonsillar Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000821:virology*; D016896:Treatment Outcome
chemical_list: D015395:Histocompatibility Antigens Class I; C098948:PSMB10 protein, human; D046988:Proteasome Endopeptidase Complex
references.citation: Int J Cancer. 2004 Dec 20;112(6):1015-9
references.pmid: 15386365
references.citation: Int J Cancer. 2009 Jul 15;125(2):362-6
references.pmid: 19330833
references.citation: Cancer Immunol Immunother. 2010 Mar;59(3):465-72
references.pmid: 19756593
references.citation: PLoS One. 2013 Oct 10;8(10):e77025
references.pmid: 24130830
references.citation: Int J Cancer. 2013 Apr 1;132(7):1565-71
references.pmid: 22949073
references.citation: Transl Oncol. 2012 Feb;5(1):48-55
references.pmid: 22348176
references.citation: Int J Cancer. 2011 Jun 15;128(12):2892-7
references.pmid: 20725995
references.citation: Oral Oncol. 2009 Sep;45(9):e85-9
references.pmid: 19457708
references.citation: Oral Oncol. 2006 Jul;42(6):586-92
references.pmid: 16469526
references.citation: Histopathology. 2013 May;62(6):847-59
references.pmid: 23611358
references.citation: Crit Rev Oncol Hematol. 2002 Jan;41(1):107-22
references.pmid: 11796235
references.citation: Mol Oncol. 2007 Dec;1(3):350-5
references.pmid: 19383307
references.citation: Adv Cancer Res. 2005;93:59-89
references.pmid: 15797444
references.citation: Int J Cancer. 2006 Dec 1;119(11):2620-3
references.pmid: 16991119
references.citation: Cancer Med. 2013 Aug;2(4):507-18
references.pmid: 24156023
references.citation: Int J Cancer. 2013 Jan 1;132(1):72-81
references.pmid: 22592660
references.citation: Cancer Immunol Immunother. 2008 Feb;57(2):197-206
references.pmid: 17622526
references.citation: Int J Cancer. 2002 Nov 10;102(2):152-8
references.pmid: 12385011
references.citation: Oral Oncol. 2003 Jan;39(1):31-6
references.pmid: 12457719
references.citation: Eur J Cancer. 2013 Jul;49(11):2522-30
references.pmid: 23571147
references.citation: PLoS One. 2012;7(6):e38711
references.pmid: 22701698
references.citation: Acta Otolaryngol. 2007 Sep;127(9):988-92
references.pmid: 17712680
references.citation: Int J Cancer. 2003 Nov 1;107(2):244-9
references.pmid: 12949801
references.citation: Anticancer Res. 2012 Jan;32(1):153-61
references.pmid: 22213301
references.citation: Emerg Infect Dis. 2010 Nov;16(11):1671-7
references.pmid: 21029523
references.citation: Int J Cancer. 2010 Jun 15;126(12):2879-84
references.pmid: 19856308
references.citation: Anticancer Res. 2011 May;31(5):1515-9
references.pmid: 21617204
references.citation: Int J Oncol. 2012 Apr;40(4):965-74
references.pmid: 22134332
references.citation: Anticancer Res. 2001 Jan-Feb;21(1B):529-34
references.pmid: 11299799
references.citation: J Natl Cancer Inst. 2000 May 3;92(9):709-20
references.pmid: 10793107
references.citation: Oncogene. 2000 Oct 5;19(42):4930-5
references.pmid: 11039910
references.citation: N Engl J Med. 2010 Jul 1;363(1):24-35
references.pmid: 20530316
references.citation: Clin Cancer Res. 2005 Apr 1;11(7):2552-60
references.pmid: 15814633
references.citation: Lancet Oncol. 2010 Aug;11(8):781-9
references.pmid: 20451455
references.citation: Cancer. 2007 Oct 1;110(7):1429-35
references.pmid: 17724670
references.citation: Anticancer Res. 2003 May-Jun;23(3C):2821-8
references.pmid: 12926119
references.citation: Anticancer Res. 2008 Jul-Aug;28(4B):2077-80
references.pmid: 18751378
references.citation: Int J Cancer. 2000 May 20;89(3):300-4
references.pmid: 10861508
references.citation: EMBO J. 1997 Sep 1;16(17):5363-75
references.pmid: 9311996
references.citation: Virology. 2010 Nov 10;407(1):137-42
references.pmid: 20813390